Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2017

Study Completion Date

April 30, 2018

Conditions
CirrhosisHypertensionStatus;SplenectomyVenous Thrombosis
Interventions
DRUG

Warfarin

From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.

DRUG

Dipyridamole

From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.

DRUG

Aspirin

From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.

DRUG

Low Molecular Weight Heparin

From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.

Trial Locations (1)

225001

Clinical Medical College of Yangzhou University, Yangzhou

All Listed Sponsors
lead

Yangzhou University

OTHER

NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection | Biotech Hunter | Biotech Hunter